Investing.comDoubao · 实盘不做把握 4/10不做原因:证据不足
北京时间·🕒 发布 21:20:33·⟳ 抓取 21:20:52 +19s·⚡ 决策 10-08 21:21:52 +1m00s·19.2 天前
Simulations Plus（SLP）与某全球药企达成资助合作，将 Turin AI 平台用于在研药物的定量系统药理学建模
这是一条方向正面但内容单薄的合作公告：合作方匿名、未披露金额或里程碑、未改变业绩指引，无法建立相对公司营收/市值的重大性，缺乏可交易的预期差；相关先例也不足以校准幅度。
📄 原文Investing.com↗ 原文
Simulations Plus partners with pharma firm on AI drug modeling
By Investing.com Advertisement Advertisement Simulations Plus partners with pharma firm on AI drug modeling Company New…
不做 Simulations Plus Inc.（SLP.US）
方向正面但合作方匿名、无金额/里程碑、无指引变化，对约 3.7 亿美元市值且亏损的公司无法量化重大性，缺乏可交易预期差；无有效先例校准幅度，故不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
SLP 宣布用 Turin AI 平台为某全球药企在研项目做 QSP 建模，属获资助合作且有扩展意向，但无金额、无客户名、无指引变化，对一家 3.7 亿美元、当前亏损的小盘软件公司难以量化短线弹性，故不做。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 资助合作验证 Turin AI/QSP 平台商业化并可能扩展到更多项目，方向偏正面
- 但合作匿名且无任何金额或指引增量，无法证明对营收和市值具有重大性
主要风险
- 若后续披露大额合同或知名药企背书，可能带来重估，当前证据无法捕捉该上行情景
- 公司处于亏损状态（PE TTM 约 -5.7），常规咨询型合作对盈利改善的能见度低
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
公司 PE TTM 为负、处于亏损状态，本条合作无金额，难以支撑盈利改善的短线做多逻辑
检索:Simulations Plus SLP 近期 业绩 下修 砍单 风险 利空
先例如何影响了这次决策
对本次决策的影响:先例不足叠加重大性无法量化，直接支持 AVOID，而非给出无依据的止盈止损
方向:无可用对齐先例，方向仅凭事件性质（获资助、平台采用、扩展意向）判为小幅正面
涨幅量级:无高相似同市场先例可校准涨幅，未披露金额也使幅度无法锚定
形态:无足够样本判断见光死或高开低走
工具执行结果 · 成功 1 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 28 ms
{"result": "search_processed_events:agent query=`simulations plus nvidia turin ai drug modeling 2026 | simulations plus turin ai qsp partnership pharmaceutical company | slp funded partnership quantitative systems pharmacology tu`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 降级 stock_tools HTTP · 8,009 ms
{
原文全文
展开原文 · 7,606 字
Simulations Plus partners with pharma firm on AI drug modeling By Investing.com
Advertisement
Advertisement
Simulations Plus partners with pharma firm on AI drug modeling
Company News
Published
Oct 08, 2026, 09:20 AM
Simulations Plus partners with pharma firm on AI drug modeling
View all comments (0)
0
Simulations Plus partners with pharma firm on AI drug modeling
View all comments (0)
0
© Reuters
RESEARCH TRIANGLE PARK, N.C. - Simulations Plus Inc. (NASDAQ:SLP) announced Thursday a funded partnership with a global pharmaceutical company to apply its Turin AI platform for quantitative systems pharmacology within an active drug development program.
The collaboration will evaluate how AI-enabled exploration of mechanistic model structures can reduce the time required to build and evaluate QSP models, according to a press release statement. QSP models analyze complex biological systems to inform drug development decisions.
The pharmaceutical partner will use Turin within a hosted environment, supported by Simulations Plus scientists who will provide guidance throughout model evaluation. The partnership is intended to expand into additional therapeutic development programs.
Turin enables systematic exploration and evaluation of candidate mechanistic structures against available evidence in parallel. The platform’s capabilities were enhanced through a technical collaboration with NVIDIA announced in May 2026.
Traditional QSP development requires scientists to make choices about which biological mechanisms to include and how to structure equations, with limited ability to test alternatives. The time and expertise required to build these models has historically limited their application in drug development.
"QSP can provide powerful insight into complex biological systems, but the time and expertise required to build and evaluate these models has historically limited where and when they can be applied," said Shawn O’Connor, Chief Executive Officer of Simulations Plus. "Turin is designed to break down that barrier and make QSP practical for a broader range of development decisions."
The approach combines computational exploration with human scientific judgment, keeping the partner’s scientists engaged in every step of the QSP model-building and evaluation process.
Simulations Plus provides software and consulting solutions for pharmaceutical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Simulations Plus partners with pharma firm on AI drug modeling
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,937.60
-241.6
-0.47%
US 500
7,777.20
-24.5
-0.31%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.51
+0.43
+2.85%
Dollar Index
102.155
+0.142
+0.14%
Crude Oil WTI Futures
91.65
+3.37
+3.82%
Brent Oil Futures
104.11
+3.91
+3.90%
Natural Gas Futures
3.262
+0.059
+1.84%
Gold Futures
4,147.87
+7.17
+0.17%
Silver Futures
59.31
-0.984
-1.63%
Copper Futures
6.6105
-0.0390
-0.59%
US Soybeans Futures
1,292.00
-5.00
-0.39%
U.S. 10Y
5.292
+0.014
+0.27%
U.S. 30Y
5.669
+0.008
+0.14%
U.S. 5Y
5.05
+0.029
+0.58%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.28
-0.20
-0.19%
Euro Bund Futures
120.86
+0.05
+0.04%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
Up +32% MTD: As the tech rally spills over into these AI-picked restaurant plays
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Simulations Plus partners with pharma firm on AI drug modeling
Company News
Published
Oct 08, 2026, 09:20 AM
Simulations Plus partners with pharma firm on AI drug modeling
View all comments (0)
0
Simulations Plus partners with pharma firm on AI drug modeling
View all comments (0)
0
© Reuters
RESEARCH TRIANGLE PARK, N.C. - Simulations Plus Inc. (NASDAQ:SLP) announced Thursday a funded partnership with a global pharmaceutical company to apply its Turin AI platform for quantitative systems pharmacology within an active drug development program.
The collaboration will evaluate how AI-enabled exploration of mechanistic model structures can reduce the time required to build and evaluate QSP models, according to a press release statement. QSP models analyze complex biological systems to inform drug development decisions.
The pharmaceutical partner will use Turin within a hosted environment, supported by Simulations Plus scientists who will provide guidance throughout model evaluation. The partnership is intended to expand into additional therapeutic development programs.
Turin enables systematic exploration and evaluation of candidate mechanistic structures against available evidence in parallel. The platform’s capabilities were enhanced through a technical collaboration with NVIDIA announced in May 2026.
Traditional QSP development requires scientists to make choices about which biological mechanisms to include and how to structure equations, with limited ability to test alternatives. The time and expertise required to build these models has historically limited their application in drug development.
"QSP can provide powerful insight into complex biological systems, but the time and expertise required to build and evaluate these models has historically limited where and when they can be applied," said Shawn O’Connor, Chief Executive Officer of Simulations Plus. "Turin is designed to break down that barrier and make QSP practical for a broader range of development decisions."
The approach combines computational exploration with human scientific judgment, keeping the partner’s scientists engaged in every step of the QSP model-building and evaluation process.
Simulations Plus provides software and consulting solutions for pharmaceutical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Simulations Plus partners with pharma firm on AI drug modeling
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,937.60
-241.6
-0.47%
US 500
7,777.20
-24.5
-0.31%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.51
+0.43
+2.85%
Dollar Index
102.155
+0.142
+0.14%
Crude Oil WTI Futures
91.65
+3.37
+3.82%
Brent Oil Futures
104.11
+3.91
+3.90%
Natural Gas Futures
3.262
+0.059
+1.84%
Gold Futures
4,147.87
+7.17
+0.17%
Silver Futures
59.31
-0.984
-1.63%
Copper Futures
6.6105
-0.0390
-0.59%
US Soybeans Futures
1,292.00
-5.00
-0.39%
U.S. 10Y
5.292
+0.014
+0.27%
U.S. 30Y
5.669
+0.008
+0.14%
U.S. 5Y
5.05
+0.029
+0.58%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.28
-0.20
-0.19%
Euro Bund Futures
120.86
+0.05
+0.04%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
Up +32% MTD: As the tech rally spills over into these AI-picked restaurant plays
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
d7d433a1f0· 2026-10-08 21:21 · doubao / doubao-seed-evolving-latest-version · 策略包0c89ec5cee9e当前